Document/ExhibitDescriptionPagesSize
1: 10-Q Quarterly Report HTML 1.30M
2: EX-10.1 Material Contract HTML 193K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
11: R1 Cover Page HTML 74K
12: R2 Condensed Consolidated Balance Sheets HTML 130K
13: R3 Condensed Consolidated Balance Sheets HTML 40K
(Parenthetical)
14: R4 Condensed Consolidated Statements of Income HTML 92K
15: R5 Condensed Consolidated Statements of Comprehensive HTML 43K
Income
16: R6 Condensed Consolidated Statements of Comprehensive HTML 24K
Income (Parenthetical)
17: R7 Condensed Consolidated Statements of Stockholders' HTML 84K
Equity
18: R8 Condensed Consolidated Statements of Cash Flows HTML 97K
19: R9 Organization and Summary of Significant Accounting HTML 37K
Policies
20: R10 Revenues HTML 124K
21: R11 Collaboration Agreements And Business Development HTML 56K
Activities
22: R12 Cash and Investments HTML 92K
23: R13 Fair Value Measurements HTML 59K
24: R14 Inventory HTML 34K
25: R15 Stockholders? Equity HTML 61K
26: R16 Provision For Income Taxes HTML 26K
27: R17 Net Income Per Share HTML 49K
28: R18 Commitments and Contingencies HTML 41K
29: R19 Pay vs Performance Disclosure HTML 34K
30: R20 Insider Trading Arrangements HTML 41K
31: R21 Organization and Summary of Significant Accounting HTML 55K
Policies (Policies)
32: R22 Revenues (Tables) HTML 124K
33: R23 Collaboration Agreements And Business Development HTML 45K
Activities (Tables)
34: R24 Cash and Investments (Tables) HTML 93K
35: R25 Fair Value Measurements (Tables) HTML 54K
36: R26 Inventory (Tables) HTML 35K
37: R27 Stockholders? Equity (Tables) HTML 54K
38: R28 Net Income Per Share (Tables) HTML 50K
39: R29 Organization and Summary of Significant Accounting HTML 29K
Policies (Details)
40: R30 Revenues - Revenues by Disaggregated Category HTML 43K
(Details)
41: R31 Revenues - Revenues Disaggregated by Concentration HTML 48K
Risks (Details)
42: R32 Revenues - Revenues Disaggregated by Geographic HTML 36K
Region (Details)
43: R33 Revenues - Net Product Revenues Disaggregated by HTML 36K
Product (Details)
44: R34 Revenues - Activities and Ending Reserve Balances HTML 43K
for Significant Categories of Discounts and
Allowances (Details)
45: R35 Revenues - Contract Assets and Liabilities HTML 41K
(Details)
46: R36 Collaboration Agreements And Business Development HTML 37K
Activities - Collaboration Revenues under the
Collaboration Agreement with Ipsen (Details)
47: R37 Collaboration Agreements And Business Development HTML 26K
Activities - Ipsen Collaboration Narrative
(Details)
48: R38 Collaboration Agreements And Business Development HTML 37K
Activities - Collaboration Revenues under the
Collaboration Agreement with Takeda (Details)
49: R39 Collaboration Agreements And Business Development HTML 34K
Activities - Takeda Collaboration Narrative
(Details)
50: R40 Collaboration Agreements And Business Development HTML 30K
Activities -Royalty Pharma Narrative (Details)
51: R41 Collaboration Agreements And Business Development HTML 34K
Activities - Research Collaborations and
In-Licensing Arrangements Narrative (Details)
52: R42 Cash and Investments - Investments by Security HTML 71K
Type (Details)
53: R43 Cash and Investments - Narrative (Details) HTML 49K
54: R44 Cash and Investments - Fair Value and Gross HTML 35K
Unrealized Losses of Investments
Available-for-Sale in an Unrealized Loss Position
(Details)
55: R45 Cash and Investments - Fair Value of Cash HTML 30K
Equivalents and Investments by Contractual
Maturity (Details)
56: R46 Fair Value Measurements (Fair Value Hierarchy) HTML 69K
(Details)
57: R47 Fair Value Measurements - Narratives (Details) HTML 31K
58: R48 Inventory (Details) HTML 34K
59: R49 Stockholders' Equity - Narrative (Details) HTML 98K
60: R50 Stockholders? Equity - Schedule of Allocated HTML 30K
Employee Stock-Based Compensation Expense
(Details)
61: R51 Stockholders? Equity - Schedule of Employee HTML 42K
Service Share - Based Compensation Expense
(Details)
62: R52 Stockholders? Equity - Estimate Grant-Date Fair HTML 41K
Value (Details)
63: R53 Provision For Income Taxes (Details) HTML 23K
64: R54 Net Income Per Share - Computation of Basic and HTML 56K
Diluted Net Income Per Share (Details)
65: R55 Net Income Per Share - Potential Shares of Common HTML 26K
Stock Not Included in the Computation of Diluted
Net Income Per Share (Details)
66: R56 Commitments and Contingencies (Details) HTML 29K
69: XML IDEA XML File -- Filing Summary XML 129K
67: XML XBRL Instance -- exel-20230630_htm XML 1.54M
68: EXCEL IDEA Workbook of Financial Report Info XLSX 120K
7: EX-101.CAL XBRL Calculations -- exel-20230630_cal XML 156K
8: EX-101.DEF XBRL Definitions -- exel-20230630_def XML 472K
9: EX-101.LAB XBRL Labels -- exel-20230630_lab XML 1.42M
10: EX-101.PRE XBRL Presentations -- exel-20230630_pre XML 845K
6: EX-101.SCH XBRL Schema -- exel-20230630 XSD 135K
70: JSON XBRL Instance as JSON Data -- MetaLinks 415± 611K
71: ZIP XBRL Zipped Folder -- 0000939767-23-000079-xbrl Zip 390K
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D.,
the President and Chief Executive Officer of Exelixis, Inc. (the “Company”), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:
1.The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2023, to which this Certification is attached as Exhibit 32.1 (the “Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
In Witness Whereof, the undersigned have set their hands hereto as of the 1st day of August 2023.
